SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is trending as a high-volatility short squeeze play, with traders closely monitoring its exceptionally low float and rising borrow rates that are forcing shorts to cover positions. The community is actively debating the stock's potential to reach triple-digit prices, while balancing excitement for parabolic gains against warnings of impending dilution and the risks of a sharp reversal.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh strong earnings beats and positive long-term product milestones against concerns over shareholder dilution and a large executive compensation package. The community is sharply divided between bulls focusing on the production ramp of the R2 SUV and bears warning about ongoing cash burn and the potential for capital raises.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is actively discussing a potential turnaround and rotation back into the MULN crypto token, with community members coordinating to revive momentum despite significant skepticism from traders who draw parallels between these crypto movements and past controversies involving the underlying company.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox stock is facing significant volatility following a sharp post-earnings sell-off, with investors expressing intense polarization over the company's growth deceleration, mounting regulatory and child-safety concerns, and the long-term viability of its engagement metrics. While some community members see the depressed valuation as a deep-value buying opportunity for a long-term recovery, others are actively shorting the stock, citing management's guidance cuts and persistent structural challenges as signs of a weakening platform.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its identity as a global cannabis culture project on the Solana blockchain, emphasizing long-term growth and cultural alignment over short-term speculation. Participants are actively discussing its potential for dispensary utility and long-term ecosystem development while preparing for upcoming culture-focused events.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors react to a powerful earnings report that showcased record cloud revenue growth and robust AI integration, driving shares to all-time highs. The market is currently fixated on whether the company's aggressive AI infrastructure spending will continue to translate into sustainable, high-margin revenue growth compared to its mega-cap peers.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following a significant earnings beat and positive guidance, which has fueled a sharp post-market rally and helped catalyze a broader recovery in sentiment for the enterprise software sector. The community is actively debating whether this performance marks a sustainable turnaround for SaaS companies or a temporary relief rally amid ongoing concerns about AI-driven disruption.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom is trending as investors react to preliminary fourth-quarter revenue results that exceeded expectations and signaled a potential recovery from recent growth concerns. While the stock initially surged following the guidance, the community remains divided, with active debates centered on whether this rally marks a sustainable turnaround or an opportunity to play volatility amidst lingering skepticism regarding the company's long-term management and market competition.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing significant social media buzz driven by a blowout earnings report that shattered analyst expectations for revenue and user growth. Community discussion is heavily focused on the stock's potential for a short squeeze, with many users highlighting strong monetization trends and the platform's unique value in the AI data licensing space.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently trending as investors weigh an impressive earnings beat against concerns over a significant increase in capital expenditure projected for AI infrastructure. The community remains deeply divided, with many traders viewing the stock's sharp decline as a buying opportunity for a long-term leader, while others express frustration over the company's aggressive spending and potential impact on near-term profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Erasca (NASDAQ:ERAS) Trading 8.8% Higher - What's Next?

Erasca (NASDAQ:ERAS) Trading Up 8.8% - Time to Buy...

Erasca stock sinks almost 50% after patient death in cancer drug trial

A 66-year-old man developed severe lung inflammation about a month after starting ERAS-0015 and later died after withdrawing supportive care...

Erasca (NASDAQ:ERAS) Sees Large Volume Increase on Analyst Upgrade

Erasca (NASDAQ:ERAS) Sees Strong Trading Volume After Analyst Upgrade...

Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63...

Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?

Erasca reports early ERAS-0015 data showing tumor response while rejecting Revolution Medicines' patent and trade secret allegations.read more...

<ul class="summary-bullets"><li>The death followed Grade 3 pneumonitis in a 66-year-old pancreatic cancer patient receiving a 24 mg dose.</li><li>ERAS-0015 showed strong early tumor response rates, including 62% in KRAS-mutant lung cancer.</li><li>Additional data from the Auroras-1 trial are expected in 2027, while results from its other candidate, ERAS-4001, are expected later this year.</li></ul>Shares of Erasca, Inc. (ERAS) plunged nearly 40% in extended trading on Monday after investors spotted a treatment-related death buried within safety disclosures, even as the company flagged strong early tumor response rates from a Phase 1 study of its experimental cancer therapy ERAS-0015.<a href="https://stocktwits.com/symbol/ERAS">ERAS stock</a> slid nearly 11% on Monday, logging its worst session in nearly eight months.&nbsp;<h2 class="st-heading-2">Treatment-Related Death Surfaces In ERAS Phase 1 Trial</h2>According to a fresh filing, one patient experienced Grade 3 pneumonitis that progressed to a treatment-related death. The patient was a 66-year-old male with metastatic pancreatic cancer receiving a 24 mg dose of ERAS-0015 who had pulmonary metastases and prior lung procedures before entering the study.&nbsp;The patient later discontinued treatment after developing pneumonitis one month after therapy initiation and later died following withdrawal of supportive care.<h2 class="st-heading-2">ERAS Cancer Trial Shows Strong Early Cancer Responses&nbsp;</h2>Alongside the safety update, Erasca reported strong early response signals from the company’s Auroras-1 study across KRAS-mutant cancers. In previously treated non-small cell lung cancer, ERAS-0015 showed a 62% tumor response rate at eight weeks, rising to 75% among patients who had already received immunotherapy and platinum chemotherapy. In pancreatic cancer, the therapy showed a 40% response rate at fourteen weeks, with most responding patients still on treatment at the time of analysis.The company also reported that all 14 evaluable patients showed large reductions in circulating tumor DNA levels. Based on these results, Erasca selected 24 mg and 32 mg once daily as the doses to move forward into expansion studies.&nbsp;Looking ahead, the company expects additional monotherapy expansion and combination dose-escalation data from the Auroras-1 study in the first half of 2027. Preliminary Phase 1 data for ERAS-4001, its pan-KRAS inhibitor program, is expected in the second half of this year.<h2 class="st-heading-2">RevMed Patent Claims Add Pressure&nbsp;</h2>Separately, Erasca disclosed in the new filing that it received a letter from the legal counsel for Revolution Medicines alleging that ERAS-0015 may infringe compositions claimed in a U.S. patent under the doctrine of equivalents. The letter also alleged possible trade-secret misappropriation from a third-party patent relating to ERAS-0015 and challenged comparisons between ERAS-0015 and RMC-6236 made in public disclosures.RMC-6236 is a cancer drug being developed by Revolution Medicines to treat tumors driven by KRAS mutations. Unlike older targeted therapies that focus on a single mutation, it works across multiple KRAS mutation types, which are common in cancers such as lung and pancreatic cancer. It is still in early-stage clinical testing.Revolution Medicines requested that Erasca cease manufacturing, using or selling ERAS-0015 outside Hatch-Waxman safe-harbor protections and stop making “untrue comparative statements.” However, Erasca said it believes the allegations are without merit and intends to contest them vigorously.<h2 class="st-heading-2">How Do Retail Traders Feel About ERAS?</h2>On Stocktwits, retail sentiment for ERAS slipped to ‘bearish’&nbsp; from ‘neutral’ levels from a day ago amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/eras_ss_png_c88c88c3a3.webp" alt="eras ss.png" width="980" height="152"><figcaption>ERAS sentiment and message volume as of April 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/docsamiles/message/651583972">said</a>, “Long-term effert on stock price depends on Erasca's relationship with FDA and whether a clinical hold is issued. Honesty and timeliness is paramount in FDA interactions.”<stembedurl>https://stocktwits.com/docsamiles/message/651583972</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/FDAvalid/message/651581652">said</a>, “The Reality Check: If a drug makes a patient "decide" to stop all care, the toxicity is the problem, not the patient. You aren't buying a dip; you're buying a bio-hazard.”<stembedurl>https://stocktwits.com/FDAvalid/message/651581652</stembedurl>ERAS stock has surged nearly 1,300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-stock-crash-retail-eye-saudi-pif-buyout/cZB8j0uRe5d">Lucid Stock Is Crashing Hard And Leaves Retail Wondering If Saudi PIF Buyout Is A Good Exit Strategy</a>

In this photo illustration, the Erasca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death 

ERAS Stock - Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Equity

Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals

Erasca (NASDAQ:ERAS) presented a preliminary Phase 1 data update for ERAS-0015 (also referred to as ERAS-15), which management described as a pan-RAS molecular glue, highlighting early signals of...

Erasca (NASDAQ:ERAS) Shares Gap Down - What's Next?

Erasca (NASDAQ:ERAS) Shares Gap Down - What's Next...

Stifel Nicolaus Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price

Stifel Nicolaus upped their price target on shares of Erasca from $20.00 to $30.00 and gave the company a "buy" rating in a report on Monday...

Erasca (NASDAQ:ERAS) Stock Price Down 6.3%  - Time to Sell?

Erasca (NASDAQ:ERAS) Shares Down 6.3% - Time to Sell...

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

ERAS
Erasca Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ERAS News

ERASErasca Inc